Stock listing
NASDAQ:COAG Hemab Therapeutics Holdings, Inc. Stock
Home listing (NASDAQ) of Hemab Therapeutics Holdings, Inc.
Follow Hemab Therapeutics Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:COAG
$38.77 USD -4.04 (-9.4%)
Close on Nov 10, 2026
- Day range
- $36.57 – $44.15 USDNov 10, 2026
- Volume
- 817,138 sharesNov 10, 2026
- Market cap
- $1.81B USDAt the close on Nov 10, 2026 · price × 46.71M shares outstanding
- Traded on an average day
- $18.92M USDMedian day 390,037 shares · last 3 months, Aug 10, 2026 – Nov 10, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:COAG · Home | $38.77 USD | -4.04 (-9.4%) | 817,138 | $40.09 | $44.15 | $36.57 | $42.81 | Close on Nov 10, 2026 |
Daily closes
Last 3 months, Aug 10, 2026 – Nov 10, 2026 · NASDAQ:COAG · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $38.77 | -4.04 | -9.4% | $40.09 | $44.15 | $36.57 | 817,138 | |
| $42.81 | -6.21 | -12.7% | $49.92 | $50.22 | $42.63 | 1,095,821 | |
| $49.02 | +3.45 | +7.6% | $46.18 | $49.12 | $45.52 | 427,919 | |
| $45.57 | +0.48 | +1.1% | $45.00 | $45.89 | $43.96 | 456,496 | |
| $45.09 | +1.99 | +4.6% | $45.00 | $45.14 | $41.96 | 499,700 | |
| $43.10 | +1.92 | +4.7% | $41.90 | $44.36 | $41.15 | 465,768 | |
| $41.18 | -0.27 | -0.7% | $41.67 | $42.91 | $39.96 | 343,874 | |
| $41.45 | +1.03 | +2.5% | $40.34 | $42.85 | $39.38 | 765,549 | |
| $40.42 | +1.92 | +5.0% | $38.89 | $42.23 | $38.75 | 1,195,908 | |
| $38.50 | +0.10 | +0.3% | $38.23 | $38.78 | $37.26 | 414,023 | |
| $38.40 | +2.38 | +6.6% | $36.35 | $38.58 | $35.64 | 380,009 | |
| $36.02 | +1.62 | +4.7% | $34.73 | $36.39 | $34.39 | 269,190 | |
| $34.40 | -0.415 | -1.2% | $34.58 | $36.70 | $33.89 | 271,177 | |
| $34.82 | -0.525 | -1.5% | $35.20 | $35.90 | $34.44 | 368,983 | |
| $35.34 | +1.17 | +3.4% | $34.17 | $36.33 | $34.13 | 388,273 | |
| $34.17 | +2.08 | +6.5% | $32.16 | $34.53 | $31.32 | 397,751 | |
| $32.09 | +2.02 | +6.7% | $30.12 | $32.37 | $29.88 | 254,486 | |
| $30.07 | -2.45 | -7.5% | $32.56 | $32.56 | $29.87 | 351,800 | |
| $32.52 | +2.58 | +8.6% | $30.20 | $33.50 | $30.20 | 478,300 | |
| $29.94 | +0.14 | +0.5% | $29.75 | $30.42 | $29.01 | 224,900 | |
| $29.80 | -0.59 | -1.9% | $30.59 | $31.05 | $29.11 | 442,000 | |
| $30.39 | -1.23 | -3.9% | $31.68 | $32.15 | $30.20 | 235,000 | |
| $31.62 | +0.73 | +2.4% | $30.65 | $33.93 | $29.98 | 619,100 | |
| $30.89 | +2.19 | +7.6% | $28.60 | $31.31 | $27.39 | 616,400 | |
| $28.70 | +0.33 | +1.2% | $28.25 | $28.98 | $27.38 | 377,200 | |
| $28.37 | -2.22 | -7.3% | $30.81 | $30.89 | $28.01 | 436,800 | |
| $30.59 | -0.52 | -1.7% | $31.11 | $31.11 | $29.76 | 294,500 | |
| $31.11 | +0.05 | +0.2% | $31.49 | $31.49 | $30.06 | 354,100 | |
| $31.06 | +0.22 | +0.7% | $30.82 | $31.35 | $29.63 | 437,800 | |
| $30.84 | -1.76 | -5.4% | $32.92 | $33.27 | $30.80 | 865,200 | |
| $32.60 | -0.52 | -1.6% | $32.99 | $33.95 | $31.80 | 452,000 | |
| $33.12 | -1.62 | -4.7% | $34.39 | $34.41 | $32.60 | 348,500 | |
| $34.74 | -0.98 | -2.7% | $35.70 | $36.10 | $34.74 | 266,500 | |
| $35.72 | -1.01 | -2.7% | $36.89 | $37.64 | $34.01 | 401,300 | |
| $36.73 | -1.52 | -4.0% | $38.38 | $38.98 | $34.99 | 417,100 | |
| $38.25 | +0.28 | +0.7% | $38.53 | $39.81 | $37.42 | 550,100 | |
| $37.97 | -3.22 | -7.8% | $41.20 | $43.21 | $37.54 | 556,800 | |
| $41.19 | -0.03 | -0.1% | $41.67 | $42.31 | $40.85 | 4,149,500 | |
| $41.22 | +0.25 | +0.6% | $41.23 | $43.47 | $40.42 | 429,000 | |
| $40.97 | +0.86 | +2.1% | $40.44 | $43.98 | $39.97 | 597,200 | |
| $40.11 | -0.36 | -0.9% | $40.15 | $40.65 | $39.29 | 256,900 | |
| $40.47 | +1.07 | +2.7% | $39.40 | $40.88 | $38.79 | 459,500 | |
| $39.40 | -0.48 | -1.2% | $40.26 | $42.48 | $38.98 | 408,100 | |
| $39.88 | -4.62 | -10.4% | $44.32 | $44.52 | $39.50 | 433,600 | |
| $44.50 | -0.07 | -0.2% | $44.77 | $46.20 | $43.05 | 429,300 | |
| $44.57 | +0.16 | +0.4% | $44.03 | $45.49 | $43.10 | 358,000 | |
| $44.41 | +0.04 | +0.1% | $43.40 | $45.49 | $43.29 | 302,000 | |
| $44.37 | -0.33 | -0.7% | $44.62 | $45.28 | $43.02 | 257,200 | |
| $44.70 | +0.68 | +1.5% | $44.51 | $46.83 | $42.71 | 325,200 | |
| $44.02 | -1.71 | -3.7% | $45.81 | $47.00 | $43.34 | 318,500 | |
| $45.73 | +0.89 | +2.0% | $44.66 | $46.43 | $43.08 | 591,600 | |
| $44.84 | -4.65 | -9.4% | $48.84 | $49.37 | $44.64 | 260,100 | |
| $49.49 | +0.30 | +0.6% | $49.15 | $51.11 | $48.61 | 355,000 | |
| $49.19 | -0.46 | -0.9% | $49.77 | $52.00 | $47.97 | 334,200 | |
| $49.65 | +2.98 | +6.4% | $46.67 | $50.36 | $46.58 | 527,159 | |
| $46.67 | -2.49 | -5.1% | $49.10 | $50.15 | $46.46 | 336,958 | |
| $49.16 | +0.96 | +2.0% | $48.85 | $53.00 | $46.99 | 391,800 | |
| $48.20 | -3.46 | -6.7% | $50.76 | $51.69 | $46.57 | 426,500 | |
| $51.66 | -0.78 | -1.5% | $53.42 | $54.05 | $50.85 | 279,900 | |
| $52.44 | -1.15 | -2.1% | $53.00 | $55.37 | $52.30 | 183,100 | |
| $53.59 | -1.35 | -2.5% | $54.78 | $55.18 | $51.77 | 208,900 | |
| $54.94 | +0.99 | +1.8% | $53.76 | $55.42 | $50.59 | 101,200 | |
| $53.95 | +0.47 | +0.9% | $54.74 | $55.18 | $52.00 | 171,400 | |
| $53.48 | +1.74 | +3.4% | $52.12 | $54.66 | $50.85 | 278,100 | |
| $51.74 | +1.87 | +3.7% | $49.87 | $52.27 | $49.62 | 251,600 | |
| $49.87 | +0.21 | +0.4% | $49.66 | $51.81 | $48.76 | 299,100 |
- Ticker
- NASDAQ:COAG
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Hemab Therapeutics to Participate in Upcoming Investor Conferences
Latest earnings call · Nov 10, 2026
Hemab Therapeutics Holdings (NASDAQ:COAG) Q3 2026 Earnings Call
Replay and transcript
Calls
Replays
Hemab Therapeutics Holdings (NASDAQ:COAG) Q3 2026 Earnings Call
Tue, Nov 10, 2026 · 8:00 AM ET
Watch Transcript
Latest news
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
Nov 9, 2026
Closed $42.81 (-12.7%) on Nov 9, 2026
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
Nov 4, 2026
Closed $45.09 (+4.6%) on Nov 4, 2026
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
Nov 3, 2026
Closed $43.10 (+4.7%) on Nov 3, 2026
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Sep 24, 2026
Closed $34.74 (-2.7%) on Sep 25, 2026
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Sep 17, 2026
Closed $41.22 (+0.6%) on Sep 17, 2026
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 11, 2026
Closed $51.74 (+3.7%) on Aug 11, 2026
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Jul 14, 2026
Closed $43.31 (+9.6%) on Jul 14, 2026
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Jul 12, 2026
Closed $39.51 (+3.9%) on Jul 13, 2026
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Closed $28.60 (+2.7%) on May 27, 2026
Financings
Public offering of common stock
May 4, 2026
Closed: US$346.7M raised · US$18 a share · Goldman Sachs & Co. LLC +3
Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), Wedbush PacGrow
Hemab Therapeutics Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 13 in all · newest Nov 11, 2026 · oldest 2026
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 10, 2026
Where Hemab Therapeutics Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:COAG · Home listing · This page | NASDAQ | United States | USD |
| BOATS:COAG | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Hemab Therapeutics Holdings, Inc.